Paediatric Buruli ulcer in Australia
- PMID: 31821679
- DOI: 10.1111/jpc.14704
Paediatric Buruli ulcer in Australia
Abstract
Aim: This study describes an Australian cohort of paediatric Buruli ulcer (BU) patients and compares them with adult BU patients.
Methods: Analysis of a prospective cohort of all BU cases managed at Barwon Health, Victoria, from 1 January 1998 to 31 May 2018 was performed. Children were defined as ≤15 years of age.
Results: A total of 565 patients were included: 52 (9.2%) children, 289 (51.2%) adults aged 16-64 years and 224 (39.6%) adults aged ≥65 years. Among children, half were female and the median age was 8.0 years (interquartile range 4.8-12.3 years). Six (11.5%) cases were diagnosed from 2001 to 2006, 14 (26.9%) from 2007 to 2012 and 32 (61.5%) from 2013 to 2018. Compared to adults, children had a significantly higher proportion of non-ulcerative lesions (32.7%, P < 0.001) and a higher proportion of severe lesions (26.9%, P < 0.01). The median duration of symptoms prior to diagnosis was shorter for children compared with adults aged 16-64 years (42 vs. 56 days, P = 0.04). Children were significantly less likely to experience antibiotic complications (6.1%) compared with adults (20.6%, P < 0.001), but had a significantly higher rate of paradoxical reactions (38.8%) compared with adults aged 16-64 (19.2%) (P < 0.001). Paradoxical reactions in children occurred significantly earlier than in adults (median 17 vs. 56 days, P < 0.01). Cure rates were similarly high for children compared to adults treated with antibiotics alone or with antibiotics and surgery.
Conclusions: Paediatric BU cases in Australia are increasing and represent an important but stable proportion of Australian BU cohorts. Compared with adults, there are significant differences in clinical presentation and treatment outcomes.
Keywords: Australia; Buruli ulcer; paediatrics; paradoxical reaction.
© 2019 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).
References
-
- O'Brien DP, Athan E, Blasdell K, De Barro P. Tackling the worsening epidemic of Buruli ulcer in Australia in an information void: Time for an urgent scientific response. Med. J. Aust. 2018; 208: 287-9.
-
- Global Buruli Ulcer Initiative, World Health Organization. Buruli Ulcer (Mycobacterium ulcerans Infection): Fact Sheet. Geneva, Switzerland: World Health Organization; 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/buruli-ulcer-(mycobacte... [accessed 10 March 2019].
-
- Pak J, O'Brien DP, Quek T, Athan E. Treatment costs of Mycobacterium ulcerans in the antibiotic era. Int. Health 2012; 4: 123-7.
-
- Van der Werf TS, Van der Graaf WT, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet 1999; 354: 1013-8.
-
- George KM, Chatterjee D, Gunawardana G et al. Mycolactone: A polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999; 283: 854-7.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
